Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
Navitoclax 可增强 EGFR 靶向抗体-药物偶联物在 EGFR 表达三阴性乳腺癌 PDX 模型中的有效性
期刊:Breast Cancer Research
影响因子:6.1
doi:10.1186/s13058-020-01374-8
Jason J Zoeller, Aleksandr Vagodny, Veerle W Daniels, Krishan Taneja, Benjamin Y Tan, Yoko S DeRose, Maihi Fujita, Alana L Welm, Anthony Letai, Joel D Leverson, Vincent Blot, Roderick T Bronson, Deborah A Dillon, Joan S Brugge
